The End of Humira’s $200 Billion Drug Monopoly

<p>After 20 years, Humira – the best selling drug of all time – is finally facing direct competition. Typically, once generic drugs arrive on a market they dominate sales and deliver big savings. But Humira’s competitors, known as biosimilars, aren’t like most other generics.</p><br><p>This week, what makes this prescription drug showdown so unusual – and so important.</p><br><p>Guest:</p><p><a href="https://www.brookings.edu/experts/marta-wosinska/amp/" rel="noopener noreferrer" target="_blank">Marta Wosińska</a>, PhD, Visiting Fellow, Brookings Institution</p><br><p>Learn more and read a full transcript on <a href="https://tradeoffs.org/2023/01/26/humira-biosimilar-drug-prices" rel="noopener noreferrer" target="_blank">our website</a>.</p><br><p>Want more Tradeoffs? Sign up for our free <a href="https://tradeoffs.us3.list-manage.com/subscribe?u=6ab1fc39a0b1b15521551487c&amp;id=89c5edcb93&amp;utm_source=twitter-newsletter-signup&amp;utm_medium=twitter" rel="noopener noreferrer" target="_blank">weekly newsletter</a> featuring the latest health policy research and news.</p><br><p>Support this type of journalism today, <a href="https://tradeoffs.org/donate" rel="noopener noreferrer" target="_blank">with a gift</a>.</p><br /><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>